The U.S. Patent and Trademark Office ruled that the use of CRISPR-Cas9 in humans belongs to the Broad Institute of Massachusetts Institute of Technology, not the University of California, Berkeley.
Biotech company Psycheceutical Inc. of Ft. Lauderdale, Fla., was issued two patents by the United States Patent and Trademark Office for what it calls a “precision duplicity” approach to delivering psychedelic drugs to patients.
San Diego-based Arcturus Therapeutics Ltd. announced that the company was reassuming 100 percent of its global rights from Germany-based CureVac AG for ARCT-810, a messenger RNA (mRNA) drug to treat OTC deficiency.
The U.S. Patent and Trademark Office granted Emmanuelle Charpentier — co-founder of ERS Genomics — the University of California, and the University of Vienna their first U.S. patent covering the use of CRISPR/Cas9 for gene editing.
Hedge fund manager Kyle Bass has been given the green light to try to profit from efforts to wipe out drug patents, a move that could fuel similar strategies by other deep-pocketed investment firms. In a decision that comes as a blow to the pharmaceutical industry, a tribunal of the U.S. Patent and Trademark […]
HERTFORDSHIRE, England and PITTSBURGH, Aug. 25, 2015 /PRNewswire/ — Mylan N.V. (Nasdaq: MYL) today announced that the U.S. Patent and Trademark Office (PTO) has instituted inter partes review (IPR) proceedings against two Copaxone® 40 mg/mL patents, U.S. Patent Nos. 8,232,250 and 8,399,413, owned by Yeda Research & Development Co., Ltd. and licensed to Teva Pharmaceuticals Industries […]
A U.S. patent review board on Monday declined to review petitions brought by hedge-fund manager Kyle Bass, who has sought to employ an unusual trading strategy of challenging patents held by pharmaceutical companies and profiting from declines in their stock prices. The U.S. Patent and Trademark Office’s review board ruled against Mr. Bass’s challenge of […]
Prominent hedge fund manager Kyle Bass’s campaign to wipe out certain drug patents hit a roadblock on Monday when the U.S. Patent and Trademark Office declined to formally review two patents on Acorda Therapeutics Inc’s flagship multiple sclerosis drug, Ampyra. The decision to reject a review of the patents’ validity comes as the pharmaceutical industry […]